

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/N034715BC268EN.html>

Date: January 2022

Pages: 67

Price: US\$ 3,250.00 (Single User License)

ID: N034715BC268EN

Abstracts

Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period of time (days or weeks) but, after the initial episode, no recurrence. It is now recognized that most patients satisfying current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months or years.

This report contains market size and forecasts of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Global, including the following market information:

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Neuromyelitis Optica Spectrum Disorder (NMOSD) market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Intravenous Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Neuromyelitis Optica Spectrum Disorder (NMOSD) include F. Hoffmann-La Roche Ltd, Alexion Pharmaceuticals, RemeGen, Nihon Pharmaceutical, Harbour BioMed, Lundbeck, Bionure, Opexa Therapeutics and TG Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neuromyelitis Optica Spectrum Disorder (NMOSD) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Segment Percentages, by Type, 2021 (%)

Intravenous

Oral

Subcutaneous

Others

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Others

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Neuromyelitis Optica Spectrum Disorder (NMOSD) revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Neuromyelitis Optica Spectrum Disorder (NMOSD) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

F. Hoffmann-La Roche Ltd

Alexion Pharmaceuticals

RemeGen

Nihon Pharmaceutical

Harbour BioMed

Lundbeck

Bionure

Opexa Therapeutics

TG Therapeutics

Bio-Thera Solutions

Boston Pharmaceuticals

Cour Pharmaceutical

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD) OVERALL MARKET SIZE

- 2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size: 2021 VS 2028
- 2.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players in Global Market
- 3.2 Top Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies Ranked by Revenue
- 3.3 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue by Companies
- 3.4 Top 3 and Top 5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Players in Global Market

3.6.1 List of Global Tier 1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies

3.6.2 List of Global Tier 2 and Tier 3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Markets, 2021 & 2028

4.1.2 Intravenous

4.1.3 Oral

4.1.4 Subcutaneous

4.1.5 Others

4.2 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue & Forecasts

4.2.1 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2022

4.2.2 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2023-2028

4.2.3 By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

5.1.4 Others

5.2 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue & Forecasts

5.2.1 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2022

5.2.2 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2023-2028

5.2.3 By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2021 & 2028

6.2 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue & Forecasts

6.2.1 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2022

6.2.2 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2023-2028

6.2.3 By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028

6.3.2 US Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.3.3 Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.3.4 Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028

6.4.2 Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.4.3 France Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.4.4 U.K. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.4.5 Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.4.6 Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.4.7 Nordic Countries Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.4.8 Benelux Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028

6.5.2 China Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.5.3 Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.5.4 South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.5.5 Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.5.6 India Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028

6.6.2 Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.6.3 Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028

6.7.2 Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.7.3 Israel Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.7.4 Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

6.7.5 UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 F. Hoffmann-La Roche Ltd

7.1.1 F. Hoffmann-La Roche Ltd Corporate Summary

7.1.2 F. Hoffmann-La Roche Ltd Business Overview

7.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings

7.1.4 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)

7.1.5 F. Hoffmann-La Roche Ltd Key News

7.2 Alexion Pharmaceuticals

7.2.1 Alexion Pharmaceuticals Corporate Summary

7.2.2 Alexion Pharmaceuticals Business Overview

7.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD)

Major Product Offerings

7.2.4 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD)

Revenue in Global Market (2017-2022)

7.2.5 Alexion Pharmaceuticals Key News

7.3 RemeGen

7.3.1 RemeGen Corporate Summary

7.3.2 RemeGen Business Overview

7.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings

7.3.4 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)

7.3.5 RemeGen Key News

7.4 Nihon Pharmaceutical

7.4.1 Nihon Pharmaceutical Corporate Summary

7.4.2 Nihon Pharmaceutical Business Overview

7.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings

7.4.4 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)

7.4.5 Nihon Pharmaceutical Key News

7.5 Harbour BioMed

7.5.1 Harbour BioMed Corporate Summary

7.5.2 Harbour BioMed Business Overview

7.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings

7.5.4 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)

7.5.5 Harbour BioMed Key News

7.6 Lundbeck

7.6.1 Lundbeck Corporate Summary

7.6.2 Lundbeck Business Overview

7.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings

7.6.4 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)

7.6.5 Lundbeck Key News

7.7 Bionure

- 7.7.1 Bionure Corporate Summary
- 7.7.2 Bionure Business Overview
- 7.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
- 7.7.4 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
- 7.7.5 Bionure Key News
- 7.8 Opexa Therapeutics
 - 7.8.1 Opexa Therapeutics Corporate Summary
 - 7.8.2 Opexa Therapeutics Business Overview
 - 7.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
 - 7.8.4 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
 - 7.8.5 Opexa Therapeutics Key News
- 7.9 TG Therapeutics
 - 7.9.1 TG Therapeutics Corporate Summary
 - 7.9.2 TG Therapeutics Business Overview
 - 7.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
 - 7.9.4 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
 - 7.9.5 TG Therapeutics Key News
- 7.10 Bio-Thera Solutions
 - 7.10.1 Bio-Thera Solutions Corporate Summary
 - 7.10.2 Bio-Thera Solutions Business Overview
 - 7.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
 - 7.10.4 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
 - 7.10.5 Bio-Thera Solutions Key News
- 7.11 Boston Pharmaceuticals
 - 7.11.1 Boston Pharmaceuticals Corporate Summary
 - 7.11.2 Boston Pharmaceuticals Business Overview
 - 7.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings
 - 7.11.4 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)
 - 7.11.5 Boston Pharmaceuticals Key News

7.12 Cour Pharmaceutical

7.12.1 Cour Pharmaceutical Corporate Summary

7.12.2 Cour Pharmaceutical Business Overview

7.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Major Product Offerings

7.12.4 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global Market (2017-2022)

7.12.5 Cour Pharmaceutical Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Opportunities & Trends in Global Market

Table 2. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers in Global Market

Table 3. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints in Global Market

Table 4. Key Players of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Global Market

Table 5. Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Share by Companies, 2017-2022

Table 8. Global Companies Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Type

Table 9. List of Global Tier 1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD)

Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD)

Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Neuromyelitis Optica Spectrum Disorder

(NMOSD) Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Neuromyelitis Optica Spectrum Disorder

(NMOSD) Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Neuromyelitis Optica Spectrum Disorder (NMOSD)

Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Neuromyelitis Optica Spectrum Disorder (NMOSD)

Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Neuromyelitis Optica Spectrum Disorder (NMOSD)

Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Neuromyelitis Optica Spectrum Disorder (NMOSD)

Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Neuromyelitis Optica Spectrum Disorder

(NMOSD) Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Neuromyelitis Optica Spectrum Disorder

(NMOSD) Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Neuromyelitis Optica Spectrum Disorder

(NMOSD) Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Neuromyelitis Optica Spectrum Disorder

(NMOSD) Revenue, (US\$, Mn), 2023-2028

Table 30. F. Hoffmann-La Roche Ltd Corporate Summary

Table 31. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder

(NMOSD) Product Offerings

Table 32. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder

(NMOSD) Revenue (US\$, Mn), (2017-2022)

Table 33. Alexion Pharmaceuticals Corporate Summary

Table 34. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD)

Product Offerings

Table 35. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD)

Revenue (US\$, Mn), (2017-2022)

Table 36. RemeGen Corporate Summary

Table 37. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product

Offerings

Table 38. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US\$,

Mn), (2017-2022)

Table 39. Nihon Pharmaceutical Corporate Summary

Table 40. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings

Table 41. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US\$, Mn), (2017-2022)

Table 42. Harbour BioMed Corporate Summary

Table 43. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings

Table 44. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US\$, Mn), (2017-2022)

Table 45. Lundbeck Corporate Summary

Table 46. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings

Table 47. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US\$, Mn), (2017-2022)

Table 48. Bionure Corporate Summary

Table 49. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings

Table 50. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US\$, Mn), (2017-2022)

Table 51. Opexa Therapeutics Corporate Summary

Table 52. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings

Table 53. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US\$, Mn), (2017-2022)

Table 54. TG Therapeutics Corporate Summary

Table 55. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings

Table 56. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US\$, Mn), (2017-2022)

Table 57. Bio-Thera Solutions Corporate Summary

Table 58. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings

Table 59. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US\$, Mn), (2017-2022)

Table 60. Boston Pharmaceuticals Corporate Summary

Table 61. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Offerings

Table 62. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (US\$, Mn), (2017-2022)

Table 63. Cour Pharmaceutical Corporate Summary

Table 64. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD)
Product Offerings

Table 65. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD)
Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Segment by Type in 2021
- Figure 2. Neuromyelitis Optica Spectrum Disorder (NMOSD) Segment by Application in 2021
- Figure 3. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2021
- Figure 8. By Type - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
- Figure 12. US Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028
- Figure 16. Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$,

Mn), 2017-2028

Figure 20. Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028

Figure 24. China Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 28. India Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028

Figure 30. Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share, 2017-2028

Figure 33. Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue, (US\$, Mn), 2017-2028

Figure 37. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/N034715BC268EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N034715BC268EN.html>